Dr Jorge de la Rosa | Postdoctoral Fellow

de la Rosa, Jorge

Jorge’s current work is focused on the identification and charactetization of new driver genes and therapeutic targets in human cancers by performing transposon- and CRISPR/Cas9-based screens.

I am particularly interested in understanding the molecular mechanims driving human prostate cancer progression and identifying new prostate cancer vulnerabilities that can be exploited therapeutically.

Publications

  • Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.

    Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S et al.

    Nature 2018;554;7690;62-68

  • A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.

    de la Rosa J, Weber J, Friedrich MJ, Li Y, Rad L et al.

    Nature genetics 2017;49;5;730-741

  • CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.

    Weber J, Öllinger R, Friedrich M, Ehmer U, Barenboim M et al.

    Proceedings of the National Academy of Sciences of the United States of America 2015;112;45;13982-7

  • Prelamin A causes progeria through cell-extrinsic mechanisms and prevents cancer invasion.

    de la Rosa J, Freije JM, Cabanillas R, Osorio FG, Fraga MF et al.

    Nature communications 2013;4;2268

  • Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53.

    Ugalde AP, Ramsay AJ, de la Rosa J, Varela I, Mariño G et al.

    The EMBO journal 2011;30;11;2219-32

  • PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice.

    Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G et al.

    Science (New York, N.Y.) 2010;330;6007;1104-7

  • Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.

    Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S et al.

    Nature 2018;554;7690;62-68

  • A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.

    de la Rosa J, Weber J, Friedrich MJ, Li Y, Rad L et al.

    Nature genetics 2017;49;5;730-741

  • Disentangling <i>PTEN</i>-cooperating tumor suppressor gene networks in cancer.

    de la Rosa J, Weber J, Rad R, Bradley A and Cadiñanos J

    Molecular & cellular oncology 2017;4;4;e1325550

  • CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.

    Weber J, Öllinger R, Friedrich M, Ehmer U, Barenboim M et al.

    Proceedings of the National Academy of Sciences of the United States of America 2015;112;45;13982-7

  • Luminescence-based in vivo monitoring of NF-κB activity through a gene delivery approach.

    Osorio FG, de la Rosa J and Freije JM

    Cell communication and signaling : CCS 2013;11;1;19

  • Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas.

    Cabanillas R, Astudillo A, Valle M, de la Rosa J, Álvarez R et al.

    Head & neck 2013;35;3;E80-4

  • Prelamin A causes progeria through cell-extrinsic mechanisms and prevents cancer invasion.

    de la Rosa J, Freije JM, Cabanillas R, Osorio FG, Fraga MF et al.

    Nature communications 2013;4;2268

  • Novel germline SDHD deletion associated with an unusual sympathetic head and neck paraganglioma.

    Cadiñanos J, Llorente JL, de la Rosa J, Villameytide JA, Illán R et al.

    Head & neck 2011;33;8;1233-40

  • Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53.

    Ugalde AP, Ramsay AJ, de la Rosa J, Varela I, Mariño G et al.

    The EMBO journal 2011;30;11;2219-32

  • PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice.

    Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G et al.

    Science (New York, N.Y.) 2010;330;6007;1104-7

de la Rosa, Jorge
Jorge's Timeline
2014

FEBS Postdoctoral Fellow, Wellcome Trust Sanger Institute, UK.

2013

PhD in Biochemistry and Molecular Biology, University of Oviedo, Spain.

2008

BSc in Biology, University of Oviedo, Spain.